FDA Approves Moderna mRNA Flu Vaccine mFLUSIVA for Adults 50 and Older
The US FDA approved Moderna's mRNA flu vaccine mFLUSIVA for adults 50 and older on August 5, 2026. This national regulatory decision includes standard approval for adults aged 50 to 64 and accelerated approval for those 65 and older. Clinical trials showed only a 26.6% relative reduction in confirmed flu cases compared to a standard vaccine. The vaccine is not yet available to the public and requires further confirmatory trials.
Why it matters
This development addresses the limitations of current flu vaccines by introducing an mRNA platform for older adults across the United States.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news